Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
AbbVie's JAK inhibitor, Upadacitinib Extended-Release Tablet, has been approved in China for two new indications, the treatment of nr-axSpA and AS
1 November 2023
Recently, AbbVie announced that the National Medical Products Administration (NMPA) of China has approved two new indications for its JAK inhibitor, upadacitinib extended-release tablets.
Drug Insights
4 min read
Doxofylline: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
1 November 2023
This article summarized the latest R&D progress of Doxofylline, the Mechanism of Action for Doxofylline, and the drug target R&D trends for Doxofylline.
Latest Hotspot
3 min read
The FDA has granted IND approval to Biosyngen's BST02, a groundbreaking TIL therapy for liver cancer, the first of its kind globally
1 November 2023
The US FDA has approved Biosyngen's BST02 for clinical trials. This cutting-edge TIL liver cancer therapy is a pioneer in cellular and gene therapy and is the first universal liver cancer TIL treatment to progress to the clinical stage.
Drug Insights
4 min read
An In-depth Analysis of Doravirine's R&D Progress and Mechanism of Action on Drug Target
1 November 2023
This article summarized the latest R&D progress of Doravirine, the Mechanism of Action for Doravirine, and the drug target R&D trends for Doravirine.
Valuable Targets
6 min read
Advances in Clinical Research on Neuraminidase Inhibitor
1 November 2023
The surface of the influenza virus is distributed with three important proteins, namely, hemagglutinin (HA), neuraminidase (NA), and matrix protein (M2), each playing an important role in the transmission cycle of the influenza virus.
Latest Hotspot
4 min read
Genentech's Vabysmo gets FDA authorization for use in treating Retinal Vein Occlusion (RVO)
31 October 2023
Genentech has communicated that the FDA has given approval for Vabysmo®(faricimab-svoa) to be used in treating macular edema that occurs after retinal vein occlusion.
Drug Insights
4 min read
Deep Scientific Insights on Cefazolin Sodium's R&D Progress, Mechanism of Action, and Drug Target
31 October 2023
This article summarized the latest R&D progress of Cefazolin Sodium, the mechanism of action for Cefazolin Sodium, and the drug target R&D trends for Cefazolin Sodium.
Latest Hotspot
3 min read
Tenaya Therapeutics receives FDA approval to initiate the clinical trial of TN-401 gene therapy for treating PKP2-related Arrhythmogenic Right Ventricular Cardiomyopathy
31 October 2023
Tenaya Therapeutics, a clinical-phase biotech firm focusing on heart disease treatments, announced today they've received FDA approval for their IND application to begin clinical trials for TN-401.
Drug Insights
4 min read
Exploring Camrelizumab's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
31 October 2023
This article summarized the latest R&D progress of Camrelizumab, the Mechanism of Action for Camrelizumab, and the drug target R&D trends for Camrelizumab.
Bio Sequence
2 min read
Biological Glossary | What is Cyclopeptide?
31 October 2023
A cyclopeptide is a type of peptide in which the amino acid sequence forms a cyclic rather than a linear structure.
Latest Hotspot
3 min read
Mustang Bio confirms that FDA has approved the IND application for MB-109, aimed at treating recurrent Glioblastoma and High-Grade Astrocytoma
31 October 2023
Mustang Bio, Inc., a biopharmaceutical firm conducting clinical trials and developing cell and gene therapies for difficult cancers and rare genetic diseases, announced FDA approval of their IND application for MB-109.
Bio Sequence
2 min read
Biological Glossary | What is Conserved Sequence?
31 October 2023
In biology, conserved sequences refer to molecular sequences with high similarity or identity.